Xceleron Signs Second Master Service Agreement With GSK

Xceleron has signed a second Master Service Agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Xceleron will provide analytical support to GSK and its affiliated research organizations.

As part of the deal, Xceleron will increase capacity through the acquisition of an Accelerator Mass Spectrometry (AMS) instrument.

Clinical studies supported by AMS allow early investigations of the human relevancy of new drugs and novel investigational paradigms, enhancing the drug discovery and development process.

The second agreement is focused on the rapid analyses and data turnaround for early clinical studies performed by GSK or its academic and various innovator collaborators. It is complementary to an existing agreement between the two companies in which a bioanalytical service is provided to support clinical studies for regulatory submission.

Michael Butler, CEO at Xceleron said: “We’re just pleased that GSK recognizes the value of AMS, and Xceleron’s expertise with this ultra-sensitive methodology.